Afatinib Generates Excitement in NRG1 Fusion+ Lung Cancer, But Challenges Remain

Kristi Rosa
Published: Tuesday, Sep 24, 2019
Khaled A. Tolba, MD, MBBCh, an assistant professor of medical oncology at Oregon Health and Science University

Khaled A. Tolba, MD, MBBCh

Early data suggest that afatinib (Gilotrif) is a potentially effective treatment option for patients with lung adenocarcinoma who have NRG1 fusions, said Khaled A. Tolba, MD, MBBCh, but the identification of these fusions continues to pose a challenge.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication